| Q1 2024 |
52 |
$311M |
+$34.9M |
-$28.5M |
+$6.46M |
TSM, MSFT, WFC, AMZN, KMX, GSK |
13F-HR |
5/15/2024, 09:00 AM |
| Q4 2023 |
53 |
$290M |
+$23.3M |
-$29M |
-$5.7M |
SPG, MSFT, ASML, BA, INTC, WFC |
13F-HR |
2/14/2024, 09:00 AM |
| Q3 2023 |
53 |
$260M |
+$25.2M |
-$33.7M |
-$8.53M |
MSFT, BIIB, WFC, IFF, GSK, INTC |
13F-HR |
11/14/2023, 09:00 AM |
| Q2 2023 |
55 |
$283M |
+$13.4M |
-$5.12M |
+$8.23M |
MSFT, AMZN, TSM, ASML, WFC, EPD |
13F-HR |
8/14/2023, 09:00 AM |
| Q1 2023 |
52 |
$264M |
+$6.47M |
-$14.2M |
-$7.74M |
BUD, MSFT, TSM, ASML, EPD, KHC |
13F-HR |
5/15/2023, 09:00 AM |
| Q4 2022 |
52 |
$255M |
+$10.2M |
-$16.6M |
-$6.43M |
BUD, WFC, KHC, BA, CVS, SPG |
13F-HR |
2/14/2023, 08:00 AM |
| Q3 2022 |
48 |
$241M |
+$25.1M |
-$11.9M |
+$13.2M |
CVS, WFC, MSFT, BIIB, K, EPD |
13F-HR |
11/14/2022, 08:00 AM |
| Q2 2022 |
48 |
$275M |
+$33.6M |
-$142K |
+$33.5M |
K, T, KHC, GSKXXXX, MSFT, EPD |
13F-HR |
8/15/2022, 08:01 AM |
| Q1 2022 |
48 |
$315M |
+$51M |
-$6.8M |
+$44.2M |
KHC, GSKXXXX, K, BMY, AMZN, CVS |
13F-HR |
5/16/2022, 09:28 AM |
| Q4 2021 |
54 |
$291M |
+$17.4M |
-$8.94M |
+$8.42M |
SPG, CVS, WFC, MSFT, GSKXXXX, DD |
13F-HR |
2/14/2022, 07:53 AM |
| Q3 2021 |
51 |
$285M |
+$44.4M |
-$24K |
+$44.4M |
WFC, SPG, BA, KHC, AMZN, K |
13F-HR |
11/15/2021, 08:21 AM |
| Q2 2021 |
48 |
$263M |
+$18M |
-$305K |
+$17.7M |
WFC, AMZN, XOM, SPG, PAA, BIIB |
13F-HR |
8/16/2021, 09:11 AM |
| Q1 2021 |
43 |
$228M |
+$59.8M |
-$6.97M |
+$52.8M |
WFC, XOM, K, KHC, BA, GSKXXXX |
13F-HR |
5/14/2021, 08:49 AM |
| Q4 2020 |
46 |
$185M |
+$20M |
-$763K |
+$19.2M |
JWN, DD, MSFT, WFC, KHC, PAA |
13F-HR |
2/12/2021, 07:33 AM |
| Q3 2020 |
36 |
$142M |
+$22M |
-$587K |
+$21.5M |
MSFT, INTC, CMP, BIIB, DD, BMY |
13F-HR |
11/9/2020, 10:45 AM |
| Q2 2020 |
38 |
$137M |
+$21.9M |
-$328K |
+$21.5M |
AMZN, MSFT, DD, KHC, K, T |
13F-HR |
8/4/2020, 10:57 AM |
| Q1 2020 |
36 |
$104M |
+$13.7M |
-$4.97M |
+$8.7M |
AMZN, BIIB, MSFT, BMY, K, SRCL |
13F-HR |
4/29/2020, 04:07 PM |
| Q4 2019 |
50 |
$141M |
|
|
|
JWN, MSFT, BMY, BIIB, T, CVS |
13F-HR |
2/14/2020, 09:44 AM |
| Q4 2013 |
38 |
$66.9M |
|
|
|
RTN, AXP, BAC, AAPL, GS, JNJ |
13F-HR |
2/7/2014, 12:16 PM |